Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidanc...(e becoming effective Shire Limited was ....)

substituted for Shire plc as principal obligor under Shire's $1.1

billion 2.75 per cent convertible bond due 2014 originally issued by

Shire plc (and the terms and conditions of such bonds were accordingly

amended).

- Shire incurred costs associated with the introduction of the new

holding company of $12.2 million in the six months to June 30, 2008.

Completion of acquisition of METAZYM

- On June 4, 2008 Shire completed the acquisition of the global rights to

the clinical candidate arylsulfatase-A, currently known as METAZYM,

from Zymenex for $135 million in cash (see Pipeline Highlights above).

This acquisition is expected to bring forward Shire's entry into the

MLD market.

Sale of non-core assets

- Following the transfer of the relevant marketing consents

Shire recognised previously deferred gains of $9.1 million arising from

product divestments in 2007, including $8.6 million from the sale of

non-core products to Laboratorios Almirall S.A ("Almirall") in 2007.

HGT analyst day

- Shire is planning an analyst day for November 18, 2008 in

Lexington, Massachusetts - specific details will be issued nearer the

date.

Share purchases

- In the three months to June 30, 2008 1.4 million American

Depositary Shares ("ADSs") were acquired by the Employee Share

Ownership Trust ("ESOT") for a cash consideration of $71.0 million

(2007: $55.5 million) at an average ADS price of $50.12.

Board changes

- On June 18, 2008 Shire's former Chief Financial Officer,

Angus Russell, became Chief Executive Officer and Shire's former Chief

Executive Officer Matthew Emmens became Chairman and Non-Executive

Director. Shire's former Chairman, Dr James Cavanaugh, retired from the

Shire Board and David Kappler becam
'/>"/>